Although most of this website is geared towards educating the lay public, we also provide select information for health care providers and researchers.

The research at Hopkins is broad and deep, and ranges from familial risk, through precursor lesions, the genetics of invasive cancer, and the process of metastatic spread. Our research also includes new approaches to treating established disease. The Skip Viragh Center's efforts focus primarily on immunotherapy. In the Goldman Center, our research on novel therapies primarily targets genetic vulnerabilities.

Research Laboratories and Programs

Genetics of Pancreatic Cancer

For decades a handful of genes have been known to be somatically mutated in pancreatic cancer, In 1990s Scott Kern revolutionized the field with the demonstration that the p16/CDKN2A gene is inactivated in pancreatic cancer, and with his discovery of the SMAD4 gene.

Study of Familial Pancreatic Cancer

Dr. Alison Klein in the Departments of Oncology and Pathology heads the National Familial Pancreas Tumor Registry (NFPTR) at Johns Hopkins. The NFPTR is a research study aimed at identifying the causes of pancreatic cancer, particularly pancreatic cancer that runs in families. Dr. Klein has developed a program (called PancPRO) which can be used to calculate this increased risk precisely, and she is now actively hunting for the familial pancreatic cancer gene. Her research includes studies of large populations as well as smaller studies of specific families. We hope that our research will enable the early detection of pancreas cancer and lead to improved treatment of this disease, saving lives.

Michael Goggins' early detection laboratory

Dr. Michael Goggins' early detection laboratory at Hopkins is completely dedicated to developing a new screening test for the early detection of pancreatic cancer. Just as there is a PSA test for prostate cancer, so too is Dr. Goggins' lab dedicated to developing an effective screening test for pancreatic cancer. Dr. Goggins and his colleagues have demonstrated that DNA abnormalities shed from pancreatic cancers can be detected in the stool, duodenal fluid and blood of patients with pancreatic cancer. His lab hopes to use the DNA discoveries made by Dr. Kern as the basis for a new screening test. Dr. Goggins is also researching protein biomarkers, as well as abnormalities in DNA methylation as potential early detection tests.

Johns Hopkins Tissue Resource

A variety of tissues are available to scientific collaborators through the Gastrointestinal (GI) Cancer Specialized Program of Research Excellence (SPORE) Grant. This is a National Cancer Institutes grant to Johns Hopkins University. These tissues include normal tissues, precancers and invasive cancers from the pancreas and colon. Samples are available include:

  • fresh-frozen tissue,
  • xenografted tissue,
  • tissue microarrays, and
  • formalin-fixed paraffin-embedded tissue

The sharing of tissues is governed by appropriate HIPPA (health information portability and privacy) regulations and Institutional Review Board (IRB) approvals. In addition, the scientific merit of the collaborative use of these materials will be evaluated by an institutional GI SPORE scientific review group.

For more information on this shared resource, please contact Robert Anders, M.D., Ph.D. View Dr. Anders' full faculty profile.

Educational Materials and Presentations

Classification of Duct Lesions in the Pancreas

Small precancerous lesions were noted next to invasive pancreatic cancers more than a century ago (they were called “Zwischenformen;” lesions in between normal ducts and invasive cancer, by by S.P.L. Hulst in 1905). The genetic revolution described above, however, allowed the pathology team at Hopkins, lead by Ralph Hruban, to establish, using comparative genetics, that these lesions were, in fact, the precursors to invasive pancreatic cancer. A critical part of this was the establishment of a system for the Classification of Duct Lesions in the Pancreas. Today, Dr. Ralph Hruban collaborates extensively with Drs. Kern, Goggins, Klein, Vogelstein and Wood to study precursor lesions. This work focuses on the study of the earliest precursor lesions (called PanINs and IPMNs) which give rise to invasive pancreatic cancers. Just as many colon cancers arise from colon polyps, so too has this team’s research helped identify the precursor lesions which give rise to invasive pancreatic cancer. These lesions are important because, unlike invasive pancreatic cancer, these lesions are curable. Our hope is to identify those at risk for pancreatic cancer, to screen them (see below) for these precursor lesions, and then to treat them before they develop an invasive cancer.

Dr. Laura Wood in the Department of Pathology studies the "moment of invasion;" the genetic events that occur when a precursor lesion grows into an early invasive cancer. Her exciting research is aimed at discovering those events that drive a curable precancerous lesion into an incurable invasive and metastatic cancer.

Art Students' Presentations

One really unique aspect of Johns Hopkins, is that we have a Department of Art as Applied to Medicine. This department, established by the renowned Max Brödel, includes a Master's degree program. The students in this program have, over the years, collaborated with the faculty in the Sol Goldman Pancreatic Cancer Research Center to produce some amazing educational work.

Cyst Classification Teaching Tool

Several cyst-forming tumors can arise in the pancreas. These are important because some are precancerous and others are entirely benign. The team in the Sol Goldman Center has created a novel teaching tool to educate our colleagues on the key features used to classify pancreatic cysts.

New Treatments

Dr. Anne Le’s research is focused on cancer metabolism. Cancer metabolism is basically what cancer cells eat, how they digest sugars. Her research is specifically on the key enzymes of the digestion of sugars (glycolysis) and glutamine (glutaminolysis). The two enzymes she studies are lactate dehydrogenase A and glutaminase. The goal of her research is to therapeutically target the enzymes and pathways that cancer cells use as a way of treating pancreatic cancer.

Audio Interviews

Dr. Ralph Hruban, Director of the Sol Goldman Pancreatic Cancer research Center here at Johns Hopkins was interviewed on ReachMD XM 157, an XM radio station for medical professionals. In a series of three interviews Dr. Hruban discussed the state of our understanding of pancreatic cancer. Although these interviews are geared towards medical professionals, we thought you might find them educational.

To listen, click a link below. To save the file to your computer, right click and choose "save":

Dr. Joseph Herman was also interviewed on XM radio, where he discussed some treatment options and the Multi-Disciplinary Pancreatic Cancer Clinic at Johns Hopkins.

To listen, click a link below. To save the file to your computer, right click and choose "save":

The Whipple Procedure

The dissection of surgically resected pancreata can be complex. We therefore created a unique teaching video for pathologists who want to learn how to disect Whipple specimens.

Learn about the Whipple Procedure


Below is a list of recent publications from the Sol Goldman Pancreatic Cancer Research Center.

Recent Publications - 2020   

  1. Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients with Pancreatic Cancer. Clin Gastroenterol Hepatol. 18(5):1161-1169, 2020.
  2. Amini N, Rezaee N, Habib JR, Blair A, Beckman RM, Manos L, Cameron JL, Hruban RH, Weiss MJ, Fishman EK, Zaheer A, Lafaro KJ, Burkhart RA, O'Broin Lennon AM, Burns WR, He J, Wolfgang CL. Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. HPB (Oxford). 2020. Online ahead of print.
  3. Ardeljan D, Steranka, Liu C, Hruban R, Boeke J, Fenyo D, Wu P-H, Smogorzewska A, Holland A, Burns K. Cell fitness screens reveal a conflict between LINE-1 retrotransposition and DNA replication. Nat Struct Mol Biol. 27(2):168-178, 2020.
  4. Blackford A, Canto M, Klein A, Hruban R, Goggins M. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst. 112(11):1162-1169, 2020.
  5. Canto MI, Kerdsirichairat T, Yeo CJ, Hruban RH, Shin EJ, Almario JA, Blackford A, Ford M, Klein AP, Javed AA, Lennon AM, Zaheer A, Kamel IR, Fishman EK, Burkhart R, He J, Makary M, Weiss MJ, Schulick RD, Goggins MG, Wolfgang CL. Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer. J Gastrointest Surg. 24(5):1101-1110, 2020.
  6. Chu L, Solmaz B, Park S, Kawamoto S, Yuille A, Hruban R, Fishman E. Diagnostic performance of commercially available vs. in-house radiomics software in classification of CT images from patients with pancreatic ductal adenocarcinoma vs. healthy controls. Abdom Radiol (NY). 45(8):2469-2475, 2020.
  7. Chu LC, Park S, Kawamoto S, Yuille AL, Hruban RH, Fishman EK. Pancreatic cancer imaging: a new look at an old problem. Curr Probl Diagn Radiol. 2020. Online ahead of print.
  8. Cristiano S, McKean D, Carey J, Bracci P, Brennan P, Chou M, Du M, Gallinger S, Goggins MG, Hassan MM, Hung RJ, Kurtz RC, Li D, Lu L, Neale R, Olson S, Petersen G, Rabe KG, Fu J, Risch H, Rosner GL, Ruczinski I, Klein AP, Scharpf RB. Bayesian copy number detection and association in large-scale studies. BMC Cancer. 20(1):856. doi: 10.1186/s12885-020-07304-3, 2020.
  9. Douville C, Cohen JD, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Schoen RE, Tie J, Gibbs P, Goggins M, Wolfgang CL, Wang TL, Shih IM, Karchin R, Lennon AM, Hruban RH, Tomasetti C, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B. Assessing aneuploidy with repetitive element sequencing. Proc Natl Acad Sci U S A. 117(9):4858-4863, 2020.
  10. Esposito I, Hruban RH, Verbeke C, Terris B, Zamboni G, Scarpa A, Morohoshi T, Suda K, Luchini C, Klimstra DS, Adsay V, Haeberle L, Saluja A, Fernandez-Del Castillo C, Sheel A, Neoptolemos JP, Isaji S, Shimosegawa T, Whitcomb DC, Campbell F; Working group for the International (IAP – APA – JPS – EPC) Consensus Guidelines for Chronic Pancreatitis. Guidelines on the Histopathology of Chronic Pancreatitis. Recommendations From the Working Group for the International Consensus Guidelines for Chronic Pancreatitis in Collaboration With the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. Pancreatology. 20(4):586-593, 2020.
  11. Faghih M, Noë M, Mannan R, Kamel IR, Zaheer A, Kalyani RR, Hall E, Afghani E, Warren D, Desai N, Sun Z, Walsh C, Makary MA, Goggins M, Hruban RH, He J, Singh VK. Pancreatic volume does not correlate with histologic fibrosis in adult patients with recurrent acute and chronic pancreatitis. Pancreatology. 20(6):1078-1084, 2020.
  12. Felsenstein M, Trujillo MA, Huang B, Nanda N, Jiang Z, Jeong YI, Pfluger M, Goggins MG, Hruban RH, Thompson ED, Heaphy CM, Roberts NJ, Wood L. Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Lab Invest. 100(7):1003-1013, 2020.
  13. Fouladi D, Raman S, Hruban R, Fishman E, Kawamoto S. Invasive Intraductal Papillary Mucinous Neoplasms: CT Features of Colloid Carcinoma Versus Tubular Adenocarcinoma of the Pancreas. AJR Am J Roentgenol. 214(5):1092-1100, 2020.
  14. Fujikura K, Hosoda W, Felsenstein M, Song Q, Reiter JG, Zheng L, Beleva Guthrie V, Rincon N, Dal Molin M, Dudley J, Cohen JD, Wang P, Fischer CG, Braxton AM, Noë M, Jongepier M, Fernández-del Castillo C, Mino-Kenudson M, Schmidt CM, Yip-Schneider M, Lawlor RT, Salvia R, Roberts NJ, Thompson ED, Karchin R, Lennon AM, Jiao Y, Wood LD. Multi-region whole exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut. 2020. Online ahead of print.
  15. Fujikura K, Hutchings D, Braxton A, Zhu Q, Laheru D, Hruban R, Thompson E, Wood L. Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Mod Pathol. 33(10):2026-2034, 2020.
  16. Gao S, Pu N, Yin H, Li J, Chen Q, Yang M, Lou W, Chen Y, Zhou G, Li C, Li G, Yan Z, Liu L, Yu J, Wang X. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Ther Adv Med Oncol. 12:1758835920953728. doi: 10/1177/1758835920953728, 2020.
  17. Ghoneim DH, Zhu J, Zheng W,…Klein A, Stolzenberg-Solomon R, Shu X-O, Wu L. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev. 29(12):2735-2739, 2020.
  18. Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman E, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) consortium. Gut. 69(1):7-17, 2020.
  19. Haj-Mirzaian A, Kawamoto S, Zaher A, Hruban RH, Fishman EK, Chu LC. Pitfalls in the MDCT of pancreatic cancer: stragies for minimizing errors. Abdom Radiol. 45(2):457-478, 2020.
  20. Hong SM, Jung D, Kiemen A, Gaida MM, Yoshizawa T, Braxton AM, Noë M, Lionheart G, Oshima K, Thompson ED, Burkhart R, Wu PH, Wirtz D, Hruban RH, Wood LD. Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. Mod Pathol. 33(4):639-647, 2020.
  21. Hu H, Ahu Y, Pu N, Burkhart RA, Burns W, Laheru D, Zheng L, He J, Goggins MG, Yu J. Association of germline variants in human DNA damage repair genes and response to adjuvant chemotherapy in resected pancreatic ductal adenocarcinoma. J Am Coll Surg. 231(5):527-535, 2020.
  22. Huang B, Trujillo MA, Fujkura K, Qiu M, Chen F, Felsenstein M, Zhou C, Skaro M, Gauthier C, Macgregor-Das A, Hutchings D, Hong SM, Hruban RH, Eshleman JR, Thompson ED, Klein AP, Goggins M, Wood LD, Roberts NJ. Molecular characterization of organoids derived from pancreatic Intraductal papillary mucinous neoplasms. J Pathol. 252(3):252-262, 2020.
  23. Huang W, Navarro-Serer B, Jeong YJ, Chianchiano P, Xia L, Luchini C, Veronese N, Dowiak C, Ng T, Trujillo MA, Huang B, Pflüger MJ, Macgregor-Das AM, Lionheart G, Jones D, Fujikura K, Nguyen-Ngoc KV, Neumann N, Groot VP, Hasanain A, van Oosten AF, Fischer SE, Gallinger S, Singhi AD, Zureikat AH, Brand RE, Gaida MM, Heinrich S, Burkhart RA, He J, Wolfgang CL, Goggins MG, Thompson ED, Roberts NJ, Ewald AJ, Wood LD. Pattern of invasion in human pancreatic cancer organoids is associated with loss of SMAD4 and clinical outcome. Cancer Res. 80(13):2804-2817, 2020.
  24. Kim JY, Brosnan-Cashman JA, Kim J, An S, Lee KB, Kim H, Park DY, Jang KT, Oh YH, Hruban RH, Heaphy CM, Hong SM. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumors. Pathology. 52(3):336-347, 2020.
  25. Kim J, Yuan C, Babic A, Bao Y, Clish CB, Pollak MN, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Pandharipande PV, Brais LK, Welch MW, Ng K, Giovannucci EL, Sesso HD, Manson JE, Stampfer MJ, Fuchs CS, Wolpin BM, Kraft P. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiol Biomarkers Prev. 29(5):999-1008, 2020.
  26. Kryklyva V, Ter Linden E, Kroeze LI, de Voer RM, van der Kolk BM, Stommel MWJ, Hermans JJ, Luchini C, Wood LD, Hruban RH, Nagtegaal ID, Ligtenberg MJL, Brosens LAA. Medullary pancreatic carcinoma due to somatic POLE mutation: a distinctive pancreatic carcinoma with marked long-term survival. Pancreas. 49(7):999-1003, 2020.
  27. Lahouel K, Younes L, Danilova L, Giardiello F, Hruban R, Groopman J, Kinzler K, Vogelstein B, German D, Tomasetti C. Revisiting the tumorigenesis timeline with a data-driven generative model. Proc Natl Acad Sci U S A. 117(2):857-864, 2020.
  28. Lee SJ, Sung YN, Kim SJ, Cho H, Hruban RH, Hong SM. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: from histology to clinical applications. Pancreatology. 20(7):1486-1494, 2020.
  29. Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, Ledbetter DH, Sanfilippo F, Sheridan K, Rosica D, Adonizio CS, Hwang HJ, Lahouel K, Cohen JD, Douville C, Patel AA, Hagmann LN, Rolston DD, Malani N, Zhou S, Bettegowda C, Diehl DL, Urban B, Still CD, Kann L, Woods JI, Salvati ZM, Vadakara J, Leeming R, Bhattacharya P, Walter C, Parker A, Lengauer C, Klein A, Tomasetti C, Fishman EK, Hruban RH, Kinzler KW, Vogelstein B, Papadopoulos N. Feasibility of Blood Testing Combined With PET-CT to Screen for Cancer and Guide Intervention. Science. 369(6499):eabb9601, 2020.
  30. Macgregor-Das A, Yu J, Tamura K, Abe T, Suenaga M, Shindo K, Borges M, Koi C, Kohi S, Sadakari Y, Molin M, Almario JA, Ford M, Chuidian M, Burkhart R, He J, Hruban RH, Eshleman JR, Klein AP, Wolfgang CL, Canto MI, Goggins M. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. J Mol Diagn. 22(6):748-756, 2020.
  31. Matsubayashi H, Notohara K, Hruban RH, Satoh T, Kaneko J, Sato J, Ishiwatari H, Ashida R, Uesaka K, Kiyozumi Y, Ono H. Multiple carcinomas and intraepithelial neoplasms in a case of familial pancreatic cancer: rapid morphologcial changes in the pancreatic cyst an pathological lesions undetected by clinical images. Intern Med. 59(8):1041-1046, 2020.
  32. Mattiolo P, Fiadone G, Paolino G, Chatterjee D, Bernasconi R, Piccoli P, Parolini C, El Aidi M, Sperandio N, Malleo G, Salvia R, Brosens LA, Wood LD, Scarpa A, Lawlor RT, Luchini C. Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Arch. 2020. Online ahead of print.
  33. Miller DL, Roy-Chowdhuri S, Illei P, James A, Hruban RH, Ali SZ. Primary pancreatic Ewing sarcoma: a cytomorphologic and histopathologic study of 13 cases. J Am Soc Cytopathol. 9(6):502-512, 2020.
  34. Miyabayashi K, Baker LA, Deschenes A, Traub B, Caligiuri G, Plenker D, Alagesan B, Belleau P, Li S, Kendall J, Jang GH Kawaguchi RK, Somerville TDD, Tiriac H, Hwang GI, Burkhart RA, Roberts NJ, Wood LD, Hruban RH, Gillis J, Krasnitz A, Vakoc CR, Wigler M, Notta F, Gallinger S, Park Y, Tuveson DA. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discov. 10(10):1566-1589, 2020.
  35. Mustafa S, Hruban R, Ali S. Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomopholic review. J Am Soc Cytopathol. 9(6):586-595, 2020.
  36. Nanda N, Roberts N. ATM Serine/Threonine Kinase and its Role in Pancreatic Risk. Genes (Basel). 11(1):108. doi: 10.3390/genes11010108, 2020.
  37. Noë M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, Debeljak M, Papp E, Adleff V, White JR, Luchini C, Pea A, Scarpa A, Butturini G, Zamboni G, Castelli P, Hong SM, Yachida S, Hiraoka N, Gill AJ, Samra JS, Offerhaus GJA, Hoorens A, Verheij J, Jansen C, Adsay NV, Jiang W, Winter J, Albores-Saavedra J, Terris B, Thompson ED, Roberts NJ, Hruban RH, Karchin R, Scharpf RB, Brosens LAA, Velculescu VE, Wood LD. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun. 11(1):4085. doi: 10.1038/s41467-020-17917-8, 2020.
  38. Park S, Chu LC, Fishman EK, Yuille AL, Vogelstein B, Kinzler KW, Horton KM, Hruban RH, Zinreich ES, Fadaei Fouladi D, Shayesteh S, Graves J, Kawamoto S. Annotated normal CT data of the abdomen for deep learning: challenges and strategies for implementation. Diagn Interv Imaging. 101(1):35-44, 2020.
  39. Park S, Chu LC, Hruban RH, Vogelstein B, Kinzler KW, Yuille AL, Fouladi DF, Shayesteh S, Ghandili S, Wolfgang CL, Burkhart R, He J, Fishman EK, Kawamoto S. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Diagn Interv Imaging. 101(9):555-564, 2020.
  40. Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. 271(3):566-573, 2020.
  41. Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, Almario CV, Halloran C, Lenon AM, Costello E. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 5(7):698-710, 2020.
  42. Pflüger M, Griffin JM, Hackeng WM, Kawamoto S, Yu J, Chianchiano P, Shin E, Lionheart G, Tsai HL, Wang H, Rezaee N, Burkhart RA, Cameron JL, Thompson ED, Wolfgang CL, He J, Brosens LAA, Wood LD. The impact of clinical and pathological features on IPMN recurrence after surgical resection: long-term follow-up analysis. Ann Surg. 2020. Online ahead of print.
  43. Pu N, Gao S, Beckman R, Ding D, Wright M, Chen Z, Zhu Y, Hu H, Yin L, Beckman M, Thompson E, Hruban RH, Cameron JL, Gage MM, Lafaro KJ, Burns WR, Wolfgang CL, He J, Yu J, Burkhart RA. Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. HPB (Oxford). 2020. Online ahead of print.
  44. Pu N, Chen Q, Gao S, Liu G, Zhu Y, Yin L, Hu H, Wei L, Wu Y, Maeda S, Lou W, Yu J, Wu W. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Ann Transl Med. 7(22):645. doi: 10.21037.atm.2019.10.91, 2020.
  45. Rao AD, Shin EJ, Meyer J, Thompson EL, Fu W, W, Hu C, Fishman EK, Weiss M, Wolfgang CL, Burkhart RA, He J, Kerdsirichairat T, Herman JM, Ding K, Narang A. Evaluation of a Novel Absorable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Pract Radiat Oncol. 10(6):3508-3513, 2020.
  46. Román-Meléndez GD, Venkataraman T, Monaco DR, Larman HB. Protease Activity Profiling via Programmable Phage Display of Comprehensive Proteome-Scale Peptide Libraries. Cell Syst. 11(4):375-381, 2020.
  47. Sagara T, Debeljak M, Wright C, Anders N, Liang H, Rudek M, Ostermeier M, Eshleman J, Matsushita Y. Successful gene therapy requires targeting the vast majority of cancer cells. Cancer Biol Ther. 21(10): 946-953, 2020.
  48. Sakamoto H, Attiyeh MA, Gerold JM, Makohon-Moore AP, Hayashi A, Hong J, Kappagantula R, Zhang L, Melchor JP, Reiter JG, Heyde A, Bielski CM, Penson AV, Gonen M, Chakravarty D, O'Reilly EM, Wood LD, Hruban RH, Nowak MA, Socci ND, Taylor BS, Iacobuzio-Donahue CA. The evolutionary origins of recurrent pancreatic cancer. Cancer Discov. 10(6):792-805, 2020.
  49. Seppälä TT, Zimmerman JW, Seremo E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, Jaffee EM, Eshleman J, Szabolcs A, David RP, Ting DT, Wolfgang CL, Burkhart RA. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg. 2020. Online ahead of print.
  50. Singhi AD, Wood LD, Parks E, Torbenson MS, Felsenstein M, Hruban RH, Nikiforova MN, Wald AI, Kaya C, Nikiforov YE, Favazza L, He J, McGrath K, Fasanella KE, Brand RE, Lennon AM, Furlan A, Dasyam AK, She HJ, Lee K, Bartlett DL, Slivka A. Recurrent rearrangements in PKRACA and PRKACB in intraducatal oncocytic papillary neoplasms of the pancreas and bile duct. Gastroenterology. 158(3):573-582, 2020.
  51. Streicher SA, Klein AP, Olson SH, Kurtz RC, Amundadottir LT, DeWan AT, Zhao H, Risch HA. A pooled genome-wide association study identifies pancreatic cancer susceptibility loci on chromosome 19p12 and 19p13.3 in the full-Jewish population. Hum Genet. 2020. Online ahead of print.
  52. Tang H, Jiang L, Stolzenberg-Solomon R,…Klein A, Li D, Kraft P, Wei P. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 29(9):1784-1791, 2020.
  53. Thompson E, Roberts N, Wood L, Eshleman J, Goggins G, Kern S, Klein A, Hruban R. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol. 33(12):2544-2563, 2020.
  54. Thompson E, Wood L. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. Arch Pathol Lab Med. 144 (7): 808–815, 2020.
  55. Underwood P, Zhang D, Cameron M, Gerber M, Delitto D, Maduka M, Cooper K, Han S, Hughes S, Judge S, Judge A, Trevino J. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Cancers (Basel). 12(2):329. doi: 10.3390/cancers12020329, 2020.
  56. Winnard P, Bharti S, Sharma R, Krishnamachary B, Mironchik Y, Penet M-F, Goggins M, Maitra A, Kamel I, Horton K, Jacobs M, Bhujwalla Z. Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle. 11(6):1487-1500, 2020.
  57. Yoshizawa T, Hong S-M, Jung D, Noe M, Kiemen A, Wu P-H, Wirtz D, Hruban R, Wood L, Oshima K. Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding. J Pathol. 251(4):400-410, 2020.
  58. Yu, J Gemenetzis, Kinny-Koster B,…Burkhart R, Burns W, Goggins M, He J, Wolfgang C. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Lett. 493:245-253, 2020.
  59. Yuan, F, Hung R, Walsh N,..Goggins M,…Klein A, Stolzenberg-Solomon R. Genome-Wide Association Study Data Revel Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Res. 80(18):4004-4013, 2020.
  60. Zhang YD, Hurson AN, Zhang H… Pancreatic Cancer Case-Control Consortium (PanC4); Pancreatic Cancer Cohort Consortium (PanScan); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Renal Cancer GWAS; Testicular Cancer Consortium (TECAC), Chanock SJ, Chatterjee N, Garcia-Closas M. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat Commun. 11(1):3353. doi: 10.1038/s41467-020-16483-3, 2020.
  61. Zhang J, Lan Z, Qui G, Ren H, Zhao Y, Gu Z, Li Z, Feng L, He J, Wang C. Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin. BMC Cancer. 20(1):1065. doi: 10.1186/s12885-020-07556-z, 2020.
  62. Zhong, J, Jermusyk A, Wu, L….Goggins M,...Klein A, Smith J, Kraft P, Shi J, Petersen G, Zheng W, Amundadottir L. A Transcriptome – Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. J Natl Cancer Inst. 112(10):1003-1012, 2020.
  63. Zhu J, Shu X, Guo X, Liu D, Bao J, Milne RL, Giles GG, Wu C, Du M, White E, Risch HA, Malats N, Duell EJ, Goodman PJ, Li D, Bracci P, Katzke V, Neale RE, Gallinger S, Van Den Eeden SK, Arslan AA, Canzian F, Kooperberg C, Beane Freeman LE, Scelo G, Visvanathan K, Haiman CA, Le Marchand L, Yu H, Petersen GM, Stolzenberg-Solomon R, Klein AP, Cai Q, Long J, Shu XO, Zheng W, Wu L. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev. 29(7):1501-1508, 2020.

View All Publications (2005-2020)

Other Pathology Resources from Johns Hopkins